{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:39:19Z","timestamp":1788205159396,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hereditary Hemorrhagic Telangiectasia (HHT) is a rare vascular disorder with mucocutaneous telangiectasia. Hormones are hypothesized to play a role in reducing bleeding in these patients; however, clear evidence is currently lacking. The aim of this study was to further investigate this hypothesis by assessing the impact of altered hormonal status on HHT severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional electronic questionnaire, available in English and German, was distributed with the support of various self-help groups. It included sections on the general medical history of HHT and the influence of hormones on disease symptoms. Data were collected between March 2016 and August 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 477 respondents with HHT, 326 were female (68%). With increasing age, female patients experienced more severe epistaxis compared to male patients, with a mean age of 54 years (standard deviation\u2009\u00b1\u200911.5 years, range [28,83]). Of the 228 female patients who reported having taken hormones, 73% used them for contraception and 57% for hyper- or dysmenorrhea. Regarding hormone intake, 52% of the patients taking combined estrogen and progestin therapy experienced less epistaxis. Most female patients stated an increase in epistaxis during puberty (41%) and pregnancy (39%), predominantly in the second trimester.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In HHT, variation in levels of hormone concentrations seem to contribute to symptom severity. Off-label use of hormonal products in women with HHT may be considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov: NCT02690246, Registration Date: 2016\u201302-09.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-026-08928-2","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:54:30Z","timestamp":1774000470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of hormonal status in hereditary hemorrhagic telangiectasia \u2013 analysis of an online patient questionnaire"],"prefix":"10.1186","volume":"26","author":[{"given":"Freya","family":"Droege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kruthika","family":"Thangavelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Koeninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Huessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris A.","family":"Stuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban W.","family":"Geisthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"2","key":"8928_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/thoraxjnl-2013-203720","volume":"69","author":"JW Donaldson","year":"2014","unstructured":"Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study. Thorax. 2014;69(2):161\u20137.","journal-title":"Thorax"},{"issue":"5","key":"8928_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/00062752-199809000-00005","volume":"5","author":"DA Marchuk","year":"1998","unstructured":"Marchuk DA. Genetic abnormalities in hereditary hemorrhagic telangiectasia. Curr Opin Hematol. 1998;5(5):332\u20138.","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"8928_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng1294-345","volume":"8","author":"KA McAllister","year":"1994","unstructured":"McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345\u201351.","journal-title":"Nat Genet"},{"issue":"9","key":"8928_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1288\/00005537-199109000-00008","volume":"101","author":"AA Os","year":"1991","unstructured":"Os AA, Friedman CM, White RI Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 1991;101(9):977\u201380.","journal-title":"Laryngoscope"},{"issue":"2","key":"8928_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1046\/j.1365-2273.2001.00442.x","volume":"26","author":"H Pau","year":"2001","unstructured":"Pau H, Carney AS, Murty GE. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestations. Clin Otolaryngol Allied Sci. 2001;26(2):93\u20138.","journal-title":"Clin Otolaryngol Allied Sci"},{"issue":"4","key":"8928_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/archotol.1975.00780330042011","volume":"101","author":"MG Menefee","year":"1975","unstructured":"Menefee MG, Flessa HC, Glueck HI, Hogg SP. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). An electron microscopic study of the vascular lesions before and after therapy with hormones. Arch Otolaryngol. 1975;101(4):246\u201351.","journal-title":"Arch Otolaryngol"},{"issue":"2","key":"8928_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00004836-200302000-00013","volume":"36","author":"AM Larson","year":"2003","unstructured":"Larson AM. Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol. 2003;36(2):149\u201358.","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"8928_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/00005537-200205000-00001","volume":"112","author":"RK Shah","year":"2002","unstructured":"Shah RK, Dhingra JK, Shapshay SM. Hereditary hemorrhagic telangiectasia: a review of 76 cases. Laryngoscope. 2002;112(5):767\u201373.","journal-title":"Laryngoscope"},{"issue":"12 Pt 1","key":"8928_CR9","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1288\/00005537-198412000-00003","volume":"94","author":"SM Shapshay","year":"1984","unstructured":"Shapshay SM, Oliver P. Treatment of hereditary hemorrhagic telangiectasia by Nd-YAG laser photocoagulation. Laryngoscope. 1984;94(12 Pt 1):1554\u20136.","journal-title":"Laryngoscope"},{"issue":"5","key":"8928_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/0360-3016(93)90526-2","volume":"27","author":"S Pohar","year":"1993","unstructured":"Pohar S, Mazeron JJ, Ghilezan M, Le Bourgeois JP, Pierquin B. Management of epistaxis in Rendu-Osler disease: is brachytherapy effective? Int J Radiat Oncol Biol Phys. 1993;27(5):1073\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8928_CR11","doi-asserted-by":"publisher","unstructured":"Ficany A, Del Alamo M, Bernabeu C, Shovlin CL, Rossi E. Epistaxis prevention, treatment, and future perspectives for hereditary hemorrhagic telangiectasia. J Clin Med. 2025 Oct 30;14(21):7724. PMID: 41227119; PMCID: PMC12608258. https:\/\/doi.org\/10.3390\/jcm14217724","DOI":"10.3390\/jcm14217724"},{"issue":"15","key":"8928_CR12","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.1952.02930320016006","volume":"149","author":"HJ Koch Jr.","year":"1952","unstructured":"Koch HJ Jr., Escher GC, Lewis JS. Hormonal management of hereditary hemorrhagic talangiectasia. J Am Med Assoc. 1952;149(15):1376\u201380.","journal-title":"J Am Med Assoc"},{"issue":"3","key":"8928_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1288\/00005537-198203000-00017","volume":"92","author":"DF Harrison","year":"1982","unstructured":"Harrison DF. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope. 1982;92(3):314\u201320.","journal-title":"Laryngoscope"},{"issue":"3","key":"8928_CR14","first-page":"231","volume":"57","author":"F Droege","year":"2019","unstructured":"Droege F, Lueb C, Thangavelu K, Stuck BA, Lang S, Geisthoff U. Nasal self-packing for epistaxis in Hereditary Hemorrhagic Telangiectasia increases quality of life. Rhinology. 2019;57(3):231\u20139.","journal-title":"Rhinology"},{"issue":"1","key":"8928_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91(1):66\u20137.","journal-title":"Am J Med Genet"},{"issue":"4","key":"8928_CR16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/lary.20818","volume":"120","author":"JB Hoag","year":"2010","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010;120(4):838\u201343.","journal-title":"Laryngoscope"},{"issue":"5","key":"8928_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/lary.25669","volume":"126","author":"LX Yin","year":"2016","unstructured":"Yin LX, Reh DD, Hoag JB, Mitchell SE, Mathai SC, Robinson GM, et al. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia. Laryngoscope. 2016;126(5):1029\u201332.","journal-title":"Laryngoscope"},{"key":"8928_CR18","volume-title":"Women's health across the lifespan: A pharmacotherapeutic approach","author":"LM Borgelt","year":"2010","unstructured":"Borgelt LM. Women\u2019s health across the lifespan: A pharmacotherapeutic approach. ASHP; 2010."},{"issue":"2","key":"8928_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.maturitas.2011.05.017","volume":"70","author":"JC Stevenson","year":"2011","unstructured":"Stevenson JC. A woman\u2019s journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. Maturitas. 2011;70(2):197\u2013205.","journal-title":"Maturitas"},{"issue":"4","key":"8928_CR20","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00198-012-2062-2","volume":"24","author":"UK Moller","year":"2013","unstructured":"Moller UK, Streym S, Mosekilde L, Heickendorff L, Flyvbjerg A, Frystyk J, et al. Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study. Osteoporos Int. 2013;24(4):1307\u201320.","journal-title":"Osteoporos Int"},{"issue":"5","key":"8928_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1017\/S0022215100094354","volume":"97","author":"P Vase","year":"1983","unstructured":"Vase P, Lorentzen M. Histological findings following oestrogen treatment of hereditary haemorrhagic telangiectasia. A controlled double-blind investigation. J Laryngol Otol. 1983;97(5):427\u20139.","journal-title":"J Laryngol Otol"},{"issue":"4","key":"8928_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/bjh.13606","volume":"171","author":"UW Geisthoff","year":"2015","unstructured":"Geisthoff UW, Nguyen HL, Roth A, Seyfert U. How to manage patients with hereditary haemorrhagic telangiectasia. Br J Haematol. 2015;171(4):443\u201352.","journal-title":"Br J Haematol"},{"issue":"4","key":"8928_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/archderm.1973.01620190047011","volume":"107","author":"HC Kwaan","year":"1973","unstructured":"Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol. 1973;107(4):571\u20133.","journal-title":"Arch Dermatol"},{"issue":"13","key":"8928_CR24","first-page":"699","volume":"109","author":"S Sailer","year":"1967","unstructured":"Sailer S, Wehrschutz E. Osler-Rendu-Weber disease. Treatment with estriol succinate. Munch Med Wochenschr. 1967;109(13):699\u2013704.","journal-title":"Munch Med Wochenschr"},{"key":"8928_CR25","first-page":"25","volume":"33","author":"DF Harrison","year":"1964","unstructured":"Harrison DF. Familial haemorrhagic telangiectasia. 20 cases treated with systemic oestrogen. Q J Med. 1964;33:25\u201338.","journal-title":"Q J Med"},{"issue":"11","key":"8928_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/archotol.1977.00780280027001","volume":"103","author":"TV McCaffrey","year":"1977","unstructured":"McCaffrey TV, Kern EB, Lake CF. Management of epistaxis in hereditary hemorrhagic telangiectasia. Review of 80 cases. Arch Otolaryngol. 1977;103(11):627\u201330.","journal-title":"Arch Otolaryngol"},{"issue":"5350","key":"8928_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/bmj.2.5350.159","volume":"2","author":"EK Blackburn","year":"1963","unstructured":"Blackburn EK. Long-term treatment of epistaxis with oestrogens. Br Med J. 1963;2(5350):159\u201360.","journal-title":"Br Med J"},{"issue":"3","key":"8928_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/archotol.1977.00780200074007","volume":"103","author":"HC Flessa","year":"1977","unstructured":"Flessa HC, Glueck HI. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Management of epistaxis in nine patients using systemic hormone therapy. Arch Otolaryngol. 1977;103(3):148\u201351.","journal-title":"Arch Otolaryngol"},{"issue":"5","key":"8928_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1177\/019459988409200511","volume":"92","author":"W Richtsmeier","year":"1984","unstructured":"Richtsmeier W, Weaver G, Streck W, Jacobson H, Dewell R, Olson J. Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg. 1984;92(5):564\u201370.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"8928_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.7326\/0003-4819-109-2-171_1","volume":"109","author":"AU Haq","year":"1988","unstructured":"Haq AU, Glass J, Netchvolodoff CV, Bowen LM. Hereditary hemorrhagic telangiectasia and danazol. Ann Intern Med. 1988;109(2):171.","journal-title":"Ann Intern Med"},{"issue":"5","key":"8928_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.0954-6820.1981.tb11614.x","volume":"209","author":"P Vase","year":"1981","unstructured":"Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial. Acta Med Scand. 1981;209(5):393\u20136.","journal-title":"Acta Med Scand"},{"issue":"6","key":"8928_CR32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1046\/j.1365-2273.2000.00422-3.x","volume":"25","author":"H Pau","year":"2000","unstructured":"Pau H, Carney AS, Walker R, Murty GE. Is oestrogen therapy justified in the treatment of hereditary haemorrhagic telangiectasia: a biochemical evaluation. Clin Otolaryngol. 2000;25(6):570\u20136.","journal-title":"Clin Otolaryngol"},{"issue":"5","key":"8928_CR33","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3109\/00016489.2015.1129070","volume":"136","author":"K Minami","year":"2016","unstructured":"Minami K, Haji T. Intranasal topical estrogen in the management of epistaxis in hereditary hemorrhagic telangiectasia. Acta Otolaryngol. 2016;136(5):528\u201331.","journal-title":"Acta Otolaryngol"},{"issue":"9","key":"8928_CR34","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jama.2016.11724","volume":"316","author":"KJ Whitehead","year":"2016","unstructured":"Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, et al. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA. 2016;316(9):943\u201351.","journal-title":"JAMA"},{"issue":"1","key":"8928_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/00016489.2011.621145","volume":"132","author":"B Eivazi","year":"2012","unstructured":"Eivazi B, Werner JA, Roessler M, Negm H, Teymoortash A. Lack of significant estrogen and progesterone receptor expression in nasal telangiectasias in hereditary hemorrhagic telangiectasia: an immunohistochemical analysis. Acta Otolaryngol. 2012;132(1):86\u20139.","journal-title":"Acta Otolaryngol"},{"issue":"3","key":"8928_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1160\/TH09-07-0425","volume":"103","author":"V Albinana","year":"2010","unstructured":"Albinana V, Bernabeu-Herrero ME, Zarrabeitia R, Bernabeu C, Botella LM. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost. 2010;103(3):525\u201334.","journal-title":"Thromb Haemost"},{"issue":"2","key":"8928_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/lary.20065","volume":"119","author":"E Yaniv","year":"2009","unstructured":"Yaniv E, Preis M, Hadar T, Shvero J, Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope. 2009;119(2):284\u20138.","journal-title":"Laryngoscope"},{"issue":"2","key":"8928_CR38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4193\/Rhino09.201","volume":"49","author":"E Yaniv","year":"2011","unstructured":"Yaniv E, Preis M, Shevro J, Nageris B, Hadar T. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial. Rhinology. 2011;49(2):214\u20136.","journal-title":"Rhinology"},{"key":"8928_CR39","doi-asserted-by":"publisher","unstructured":"Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, et al. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020;173(12):989\u20131001. https:\/\/doi.org\/10.7326\/M20-1443. Epub 2020 Sep 8. PMID: 32894695.","DOI":"10.7326\/M20-1443"},{"issue":"3","key":"8928_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ajmg.1320320302","volume":"32","author":"H Plauchu","year":"1989","unstructured":"Plauchu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989;32(3):291\u20137.","journal-title":"Am J Med Genet"},{"issue":"5","key":"8928_CR41","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1542\/peds.2006-2481","volume":"118","author":"Pediatrics AAo, Adolescence Co, Obstetricians ACo, Gynecologists, Care CoAH","year":"2006","unstructured":"Pediatrics AAo, Adolescence Co, Obstetricians ACo, Gynecologists, Care CoAH. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006;118(5):2245\u201350.","journal-title":"Pediatrics"},{"key":"8928_CR42","doi-asserted-by":"publisher","unstructured":"Geisthoff U, Nguyen HL, Lefering R, Maune S, Thangavelu K, Droege F. Trauma can induce telangiectases in hereditary hemorrhagic telangiectasia. J Clin Med. 2020;9(5):1507. PMID: 32429545; PMCID: PMC7290907. https:\/\/doi.org\/10.3390\/jcm9051507.","DOI":"10.3390\/jcm9051507"},{"key":"8928_CR43","doi-asserted-by":"publisher","unstructured":"CiteAndorfer KEC, Seebauer CT, Dienemann C, Marcrum SC, Fischer R, Bohr C, et al. HHT-related epistaxis and pregnancy-a retrospective survey and recommendations for management from an otorhinolaryngology perspective. J Clin Med. 2022;11(8):2178. PMID: 35456271; PMCID: PMC9025602. https:\/\/doi.org\/10.3390\/jcm11082178.","DOI":"10.3390\/jcm11082178"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-026-08928-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-08928-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-08928-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:33:09Z","timestamp":1781641989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12884-026-08928-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8928"],"URL":"https:\/\/doi.org\/10.1186\/s12884-026-08928-2","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee of the University Duisburg-Essen (15\u20136429-BO, date of approval: 19th November 2015). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors certify that this paper or any of its contents has not been published or submitted for publication elsewhere. All authors gave permission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Urban Geisthoff is consulting and collaborating with patient organizations for HHT (www.hht.org, www.morbus-osler.de). There are no other relevant conflicts of interest or disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"388"}}